As on Thursday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) got off with the flyer as it spiked 4.81% to $4.36, before settling in for the price of $4.16 at the close. Taking a more long-term approach, ZNTL posted a 52-week range of $2.83-$23.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -20.00%. Meanwhile, its Annual Earning per share during the time was -50.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 35.18%. This publicly-traded company’s shares outstanding now amounts to $70.77 million, simultaneously with a float of $61.33 million. The organization now has a market capitalization sitting at $310.04 million. At the time of writing, stock’s 50-day Moving Average stood at $3.56, while the 200-day Moving Average is $10.05.
Zentalis Pharmaceuticals Inc (ZNTL) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Zentalis Pharmaceuticals Inc’s current insider ownership accounts for 13.75%, in contrast to 100.03% institutional ownership. According to the most recent insider trade that took place on May 31 ’24, this organization’s President, Interim CFO sold 9,597 shares at the rate of 11.98, making the entire transaction reach 114,972 in total value, affecting insider ownership by 633,680. Preceding that transaction, on May 09 ’24, Company’s Chief Medical Officer sold 3,356 for 12.62, making the whole transaction’s value amount to 42,353. This particular insider is now the holder of 373,876 in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Revenue Records
Zentalis Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 35.18% and is forecasted to reach -3.56 in the upcoming year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Let’s observe the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). It’s Quick Ratio in the last reported quarter now stands at 6.59. The Stock has managed to achieve an average true range (ATR) of 0.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.64.
In the same vein, ZNTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.75, a figure that is expected to reach -0.89 in the next quarter, and analysts are predicting that it will be -3.56 at the market close of one year from today.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Through scrutinizing the latest numbers posted by the [Zentalis Pharmaceuticals Inc, ZNTL], it can be observed that its last 5-days Average volume of 11.43 million was better the volume of 1.3 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 50.35% While, its Average True Range was 0.46.
Raw Stochastic average of Zentalis Pharmaceuticals Inc (ZNTL) in the period of the previous 100 days is set at 14.70%, which indicates a major fall in contrast to 56.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 93.88% that was lower than 144.46% volatility it exhibited in the past 100-days period.
